	US 12,268,703 B2
	Cladribine regimen for treating progressive forms of multiple sclerosis
Fernando Dangond, Weston, MA (US); and Matthias Dotzauer, Erzhausen (DE)
Assigned to ARES TRADING S.A., Eysins (CH)
Filed by ARES TRADING S.A., Eysins (CH)
Filed on Oct. 23, 2020, as Appl. No. 16/949,278.
Application 16/949,278 is a division of application No. 16/199,119, filed on Nov. 23, 2018, granted, now 10,849,919.
Claims priority of provisional application 62/590,442, filed on Nov. 24, 2017.
Prior Publication US 2021/0169912 A1, Jun. 10, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7076 (2006.01); A61K 9/20 (2006.01); A61K 38/21 (2006.01); A61P 25/00 (2006.01); A61P 37/02 (2006.01)

CPC A61K 31/7076 (2013.01) [A61K 9/20 (2013.01); A61K 9/2013 (2013.01); A61K 9/2018 (2013.01); A61K 9/205 (2013.01); A61K 38/215 (2013.01); A61P 25/00 (2018.01); A61P 37/02 (2018.01)]

30 Claims

1. A method of treating Primary Progressive Multiple Sclerosis, said method comprising:

orally administering Cladribine to a patient in need thereof at fixed dose per patient, per body weight and per treatment year, wherein said fixed dose is in a range of 1.5 mg/kg to 4.0 mg/kg.